title: Pemirolast, a new oral nonbronchodilator drug for chronic asthma.
abstract: Pemirolast is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. In this multicenter, double-blind, randomized study, 96 patients with mild asthma received pemirolast, 50 mg (n = 34); pemirolast, 25 mg (n = 31); or placebo (n = 31) BID for 6 weeks. Patients were evaluated weekly at the research centers; they maintained daily symptom diaries and measured peak expiratory flow rates twice a day. Methacholine challenge was performed at the start and end of the study. Results with pemirolast, 50 mg BID, showed statistically significant decrease in nocturnal symptoms (P = .02), in composite symptom scores (P = .02) and in bronchodilator use (P = .05) when compared with placebo. There were no statistically significant differences between treatments in pulmonary function tests or in methacholine challenge sensitivity. Pemirolast, 25 mg BID, did not differ from placebo. There were no significant adverse effects. Pemirolast, 50 mg BID, demonstrated sufficient antiasthma activity to warrant further studies in patients with more severe asthma and with higher doses.
authors.affiliation: Allergy and Asthma Medical Group and Research Center, San Diego, CA 92123.
authors.forename: J P
authors.initials: JP
authors.lastname: Kemp
authors.forename: I L
authors.initials: IL
authors.lastname: Bernstein
authors.forename: C W
authors.initials: CW
authors.lastname: Bierman
authors.forename: J T
authors.initials: JT
authors.lastname: Li
authors.forename: S C
authors.initials: SC
authors.lastname: Siegel
authors.forename: R D
authors.initials: RD
authors.lastname: Spangenberg
authors.forename: D G
authors.initials: DG
authors.lastname: Tinkelman
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000188:drug therapy; D002908:Chronic Disease; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010919:Placebos / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D006633:Histamine Antagonists; D010919:Placebos; D011725:Pyridines; D011744:Pyrimidinones; C055139:pemirolast